Assessment of potential drug–drug interactions in cancer patients in a tertiary care hospital
Indian Journal of Cancer · 2025
DOI: 10.4103/ijc.ijc_24_23 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Esha Nambiar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Katraj, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer patients are administered various chemotherapeutic agents along with supportive management, which increases the risk of potential drug–drug interactions (pDDIs). We aimed to assess the pDDIs in In-patient Department (IPD) patients receiving cancer chemotherapy in a tertiary care hospital.
Methods
A prospective, observational study was conducted in the oncology department of a tertiary care hospital for a period of 6 months. Patient information was noted in the data collection form, and pDDIs were assessed using the Micromedex® database. Mann–Whitney U, Chi-square, and Spearman’s correlation were the tests used for statistical analysis. P value of less than 0.05 was considered statistically significant.
Results
In a sample size of 145 patients having a confidence interval of 95% and response distribution of 50%, the margin of error was found to be 8.11%. Male predominance (57.2%) was seen in the study. Although the adult patient population (56.5%) dominated the study, pediatric (26.9%) and geriatric (16.6%) patients were also included. A total of 115 pDDIs were found in 41% of the total patient population, out of which 56% ( n = 64) were moderate and 44% ( n = 51) were major in severity. The number of drug interactions was found to have correlation with the number of drugs (rho = 0.2, P = 0.01) prescribed during hospital stay.
Conclusion
The present study shows that cancer patients are relatively at risk for drug–drug interactions. To avoid Adverse Drug Reaction (ADRs), harmful effects, and other undesirable clinical manifestations shown by drug–drug interactions, screening for pDDIs is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Katraj, Pune, Maharashtra, India.
- Department of Pharmacy Practice, R C Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India.
ORCID-Profile: Prasanna R Deshpande
Zitieren
APA
Nambiar, E., Biswas, A., & Deshpande, P. R. (2025). Assessment of potential drug–drug interactions in cancer patients in a tertiary care hospital. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_24_23
Vancouver
Nambiar E, Biswas A, Deshpande PR. Assessment of potential drug–drug interactions in cancer patients in a tertiary care hospital. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_24_23
BibTeX
@article{Nambiar2025,
author = {Nambiar, Esha and Biswas, Ananya and Deshpande, Prasanna R},
title = {Assessment of potential drug–drug interactions in cancer patients in a tertiary care hospital},
journal = {Indian Journal of Cancer},
year = {2025},
doi = {10.4103/ijc.ijc_24_23}
}
EUVIMED